NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) COO Sells $1,019,879.36 in Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) COO Douglas F. Kling sold 47,569 shares of the stock in a transaction on Tuesday, July 15th. The shares were sold at an average price of $21.44, for a total value of $1,019,879.36. Following the completion of the sale, the chief operating officer owned 44,000 shares of the company's stock, valued at $943,360. The trade was a 51.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

NewAmsterdam Pharma Stock Performance

NAMS stock traded up $1.06 during midday trading on Thursday, reaching $21.98. The company's stock had a trading volume of 599,934 shares, compared to its average volume of 741,886. The firm has a market capitalization of $2.47 billion, a price-to-earnings ratio of -11.69 and a beta of -0.03. NewAmsterdam Pharma Company N.V. has a 1 year low of $14.06 and a 1 year high of $27.29. The stock has a fifty day simple moving average of $19.28 and a two-hundred day simple moving average of $20.25.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.49) EPS for the quarter, missing analysts' consensus estimates of ($0.45) by ($0.04). The company had revenue of $2.98 million during the quarter, compared to analyst estimates of $1.46 million. NewAmsterdam Pharma had a negative return on equity of 37.34% and a negative net margin of 397.45%. As a group, analysts forecast that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current fiscal year.

Institutional Trading of NewAmsterdam Pharma

A number of institutional investors have recently made changes to their positions in the company. Swiss National Bank lifted its stake in shares of NewAmsterdam Pharma by 105.1% in the 4th quarter. Swiss National Bank now owns 72,000 shares of the company's stock valued at $1,850,000 after purchasing an additional 36,900 shares during the last quarter. Teacher Retirement System of Texas acquired a new stake in shares of NewAmsterdam Pharma during the 4th quarter worth about $276,000. DCF Advisers LLC lifted its position in NewAmsterdam Pharma by 162.9% in the fourth quarter. DCF Advisers LLC now owns 89,400 shares of the company's stock valued at $2,298,000 after acquiring an additional 55,400 shares during the last quarter. American Century Companies Inc. acquired a new position in NewAmsterdam Pharma during the fourth quarter worth approximately $8,907,000. Finally, KLP Kapitalforvaltning AS acquired a new position in NewAmsterdam Pharma in the fourth quarter valued at $154,000. 89.89% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on NAMS. Wall Street Zen upgraded shares of NewAmsterdam Pharma from a "sell" rating to a "hold" rating in a report on Saturday, July 5th. Stifel Nicolaus initiated coverage on shares of NewAmsterdam Pharma in a research note on Tuesday, June 10th. They set a "buy" rating and a $44.00 price target for the company. Cantor Fitzgerald initiated coverage on shares of NewAmsterdam Pharma in a research report on Wednesday, June 4th. They set an "overweight" rating and a $42.00 target price for the company. Needham & Company LLC restated a "buy" rating and set a $40.00 price target on shares of NewAmsterdam Pharma in a research report on Thursday, June 12th. Finally, The Goldman Sachs Group initiated coverage on shares of NewAmsterdam Pharma in a research note on Thursday. They set a "neutral" rating and a $27.00 price target on the stock. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $41.30.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.